Acyclovir

Generic Name: Acyclovir

Brand Names: Sitavig, Xerese, Zovirax

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₁N_₅O_₃

CAS Number: 59277-89-3

Unique Ingredient Identifier: X4HES1O11F

Background: Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.

Acyclovir was granted FDA approval on 29 March 1982.

Indication: An acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older. Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox. An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients. An acyclovir cream with hydrocortisone is indicated to treat recurrent herpes labialis, and shortening lesion healing time in patients 6 years and older. An acyclovir buccal tablet is indicated for the treatment of recurrent herpes labialis. An acyclovir ophthalmic ointment is indicated to treat acute herpetic keratitis.

Associated Conditions: Bell's Palsy, Chickenpox, Cytomegalovirus (CMV) Infections, Herpes Simplex Infections, Herpes Zoster, Herpes simplex encephalitis, Herpes simplex of the oral-labial, Herpes simplex type I reactivation, Recurrent Genital Herpes (RGH), Recurrent Herpes Labialis, VZV re-activation, Acute Genital herpes, Acute Herpes labialis, Acute Herpetic keratitis, Severe Genital herpes

Clinical Trials

A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

Phase 1

Completed

Conditions: Progressive Multiple Sclerosis

Interventions: Drug: GZ402668
Drug: placebo
Drug: acyclovir

First Posted Date: 2014-11-04

Last Posted Date: 2016-04-13

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 48

Registration Number: NCT02282826

Locations: 🇩🇪
Investigational Site Number 276001, Berlin, Germany

Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

Phase 3

Completed

Conditions: Herpes Labialis

Interventions: Drug: Acyclovir 5 percent (Reference)
Drug: Acyclovir 5 percent (Perrigo)
Drug: Placebo cream

First Posted Date: 2014-10-16

Last Posted Date: 2021-10-22

Lead Sponsor: Padagis LLC

Target Recruit Count: 4076

Registration Number: NCT02265913

Locations: 🇺🇸
Quality Clinical Research Inc, Omaha, Nebraska, United States

Bioequivalence of Two Formulations of Acyclovir

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Acyclovir

First Posted Date: 2014-10-03

Last Posted Date: 2014-10-03

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT02255734

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Phase 4

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Alemtuzumab GZ402673
Drug: cetirizine
Drug: ranitidine
Drug: methylprednisolone
Drug: aciclovir
Drug: esomeprazole
Drug: ibuprofen
Drug: paracetamol

First Posted Date: 2014-07-31

Last Posted Date: 2016-06-09

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 58

Registration Number: NCT02205489

Locations: 🇧🇪
Investigational Site Number 056001, Brussels, Belgium
🇳🇱
Investigational Site Number 528001, Breda, Netherlands
🇳🇱
Investigational Site Number 528002, Rotterdam, Netherlands

and more 17 locations

PTH - Preemptive Treatment for Herpesviridae

Phase 4

Completed

Conditions: Viral Pneumonia

Interventions: Drug: Ganciclovir
Drug: Placebo
Drug: Aciclovir

First Posted Date: 2014-06-02

Last Posted Date: 2023-04-06

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 317

Registration Number: NCT02152358

Locations: 🇫🇷
Assistance Publique - Hôpitaux de Marseille, Marseille, France

Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster

Phase 4

Completed

Conditions: Herpes Zoster

Interventions: Drug: Foscarnet Sodium
Drug: Acyclovir

First Posted Date: 2014-05-30

Last Posted Date: 2021-06-28

Lead Sponsor: Cttq

Target Recruit Count: 94

Registration Number: NCT02151240

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Phase 1

Completed

Conditions: Stage IV Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage I Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

Interventions: Drug: Carfilzomib
Biological: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin hydrochloride
Drug: Vincristine sulfate
Drug: Prednisone
Drug: Pegfilgrastim
Drug: Acyclovir

First Posted Date: 2014-02-27

Last Posted Date: 2024-05-29

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 48

Registration Number: NCT02073097

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Acyclovir Therapy for Genital Herpes Ulcers in HIV Negative African Women

Not Applicable

Completed

Conditions: Ulcers of Female Genital Organs

Interventions: Drug: Placebo
Drug: Acyclovir

First Posted Date: 2014-02-03

Last Posted Date: 2017-09-15

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 74

Registration Number: NCT02053142

Locations: 🇿🇲
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Phase 2

Completed

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Drug: Acyclovir

First Posted Date: 2014-01-28

Last Posted Date: 2018-12-19

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 28

Registration Number: NCT02047253

Locations: 🇺🇸
University of Tulane, New Orleans, Louisiana, United States
🇺🇸
Birmingham VA Medical Center, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 1 locations

Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bortezomib
Drug: Acyclovir

First Posted Date: 2013-04-16

Last Posted Date: 2020-08-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT01833143

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy